Hinagolid

Iz Wikipedije, slobodne enciklopedije
Hinagolid
(IUPAC) ime
N,N-dietil-N'-[(3S*,4aS*,10aR*)-6-hidroksi-1-propil-1,2,3,4,4a,5,10,10a-oktahidrobenzo[g]hinolin-3-il]sulfamid
Klinički podaci
AHFS/Drugs.com Internacionalno ime leka
Identifikatori
CAS broj 87056-78-8
ATC kod G02CB04
PubChem[1][2] 55645
ChemSpider[3] 2343034
UNII 80Q9QWN15M YesY
KEGG[4] D07217 YesY
ChEMBL[5] CHEMBL290962 YesY
Hemijski podaci
Formula C20H33N3O3S 
Mol. masa 395,56 g/mol
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status Prescription only
Način primene Oralno

Hinagolid (Norprolak) je selektivni agonist D2 receptor koji se koristi za tretiranje povišenih nivoa prolaktina.[6]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Joanne Wixon, Douglas Kell (2000). "Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG". Yeast 17 (1): 48–55. doi:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  6. Antonella Di Sarno, Maria Luisa Landi, Paolo Marzullo, Carolina Di Somma, Rosario Pivonello, Gaetana Cerbone, Gaetano Lombardi, Annamaria Colao (July 2000). "The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas". Clinical Endocrinology 53 (1): 53–60. doi:10.1046/j.1365-2265.2000.01016.x. 

Vidi još[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]


Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).